Drug Profile

NAV 001 - Navrogen

Alternative Names: NAV-001 - Novarogen; NAV001 - Navrogen

Latest Information Update: 25 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Navrogen
Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
Mechanism of Action Cell death stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Adenocarcinoma

Most Recent Events

18 May 2023 Navrogen plans a clinical trial for Cancer
14 Apr 2023 Pharmacodynamics data from a preclinical study in Cancer presented at the 114^th Annual Meeting of the American Association for Cancer Research (AACR-2023)
07 Nov 2022 Navrogen establishes CRADA with National Cancer Institute for the development of NAV-001 in Adenocarcinoma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com